Across TCGA pan-cancer cohorts, CPNE7 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CPNE7 data layer compared with 24 for mass-spec protein and 11 for mutation status.
The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CPNE7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CPNE7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and GBM show a favorable association.
PDAC and GBM are the cancer types where CPNE7 mass-spec protein most reproducibly stratifies survival.